Active Viral Hepatitis Diagnostics to Support Prevention/Treatment of HCC

主动病毒性肝炎诊断支持 HCC 的预防/治疗

基本信息

  • 批准号:
    8790208
  • 负责人:
  • 金额:
    $ 45.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-19 至 2016-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Active Viral Hepatitis Diagnostics to Support Prevention/Treatment of HCC Hepatocellular carcinoma (HCC) is very common in sub-Saharan Africa due to highly prevalent chronic hepatitis B (HBV) and hepatitis C (HCV) viral infection. Currently, patients in sub-Saharan Africa typically present in late stage disease, having a life expectancy of just three months. Earlier diagnosis could reduce HCC mortality in two ways: 1) patients with HBV or HCV would be staged earlier and tumors, if present, would be smaller and therefore easier to treat with alcohol ablation, the current standard of care in the region; and 2) patients identified earlier with chronic HBV or HCV could be treated with direct acting antiviral agents (DAAs) leading to reduced morbidity including less HCC. The goal of this application is to develop low cost point-of-care diagnostic tests to detect and monitor the treatment of active HBV and/or HCV infections. The first test to be developed will be an HCV core antigen qualitative test to identify patients with an active HCV infection. This assay will be ported on th LYNX immunoassay platform developed in collaboration with the Northwestern Global Health Foundation (NGHF). The test conditions developed for the LYNX p24 Antigen Rapid Lateral Flow Assay for Rapid Diagnosis of HIV Infection in Infants will be adapted to address a highly analogous problem: the detection of the HCV core antigen viral marker from plasma. The second test will be a multiplexed HBV/HCV viral load assay to determine when to initiate therapy and to monitor the viral response to DAA treatment. This assay will be ported onto the Savanna integrated nucleic acid extraction, amplification & detection system that is currently being developed in collaboration with the Quidel Corporation and NGHF. The test conditions developed for the Savanna RealTime HIV-1 Assay(R) will be used for the HBV/HCV viral load assay. Both the LYNX and the Savanna platforms have been designed for use in limited resource settings. They are inexpensive, easy to operate and robust. All reagents are provided with the test kits and no refrigeration is required. The analytical and clinical performance of these assays will be demonstrated in both laboratory and clinical validation studies at the Jos University Teaching Hospital in Jos, Nigeria. The tests will be transferred to their respective manufacturers, and regulatory approval for will be sought. The impact of earlier detection and improved monitoring of viral hepatitis will prompt earlier treatment resulting in prevention of carcinogenesis and/or earlier stage diagnosis with improved outcomes in patients in low and middle income countries.
描述(由申请人提供):主动病毒性肝炎诊断支持预防/治疗肝细胞癌(肝细胞癌)在撒哈拉以南非洲地区非常常见,因为慢性乙肝(乙肝)和丙型肝炎(丙型肝炎)病毒感染非常普遍。目前,撒哈拉以南非洲的患者通常处于晚期疾病,预期寿命只有三个月。早期诊断可以通过两种方式降低肝癌死亡率:1)携带乙肝病毒或丙型肝炎病毒的患者分期更早,如果存在肿瘤,肿瘤会更小,因此更容易通过酒精消融治疗,这是该地区目前的治疗标准;以及2) 早期确诊为慢性乙肝或丙型肝炎的患者可以使用直接作用的抗病毒药物(DAA)进行治疗,从而减少发病率,包括较少的肝癌。该应用程序的目标是开发低成本的护理点诊断测试,以检测和监测活动性乙肝病毒和/或丙型肝炎病毒感染的治疗。将开发的第一个测试将是丙型肝炎病毒核心抗原定性测试,以识别活动性丙型肝炎病毒感染的患者。这项检测将被移植到与西北全球健康基金会(NGHF)合作开发的THLynx免疫检测平台上。为Lynx p24抗原快速侧向流动分析开发的快速诊断婴儿艾滋病毒感染的测试条件将被调整,以解决一个高度相似的问题:从血浆中检测丙型肝炎病毒核心抗原病毒标志物。第二个测试将是多重的乙肝病毒/丙型肝炎病毒载量分析,以确定何时开始治疗并监测对DAA治疗的病毒反应。这项分析将被移植到萨凡纳综合核酸提取、扩增和检测系统上,该系统目前正在与Quidel公司和NGHF合作开发。为萨凡纳实时HIV-1检测(注册商标)开发的测试条件将用于乙肝病毒/丙型肝炎病毒载量检测。Lynx和Savanna平台都是为在有限的资源环境中使用而设计的。它们价格低廉,易于操作,而且坚固耐用。所有试剂都配有检测试剂盒,不需要冷藏。这些检测的分析和临床性能将在尼日利亚乔斯的乔斯大学教学医院的实验室和临床验证研究中得到验证。这些测试将被转移到各自的制造商,并将寻求监管部门的批准。更早发现和改进对病毒性肝炎的监测的影响将促使更早的治疗,从而预防癌症的发生和/或早期诊断,从而改善低收入和中等收入国家患者的结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT Leo MURPHY其他文献

ROBERT Leo MURPHY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT Leo MURPHY', 18)}}的其他基金

Admin-Core
管理核心
  • 批准号:
    10441625
  • 财政年份:
    2018
  • 资助金额:
    $ 45.06万
  • 项目类别:
Admin-Core
管理核心
  • 批准号:
    10174926
  • 财政年份:
    2018
  • 资助金额:
    $ 45.06万
  • 项目类别:
Career Enhancement Core
职业提升核心
  • 批准号:
    10242894
  • 财政年份:
    2017
  • 资助金额:
    $ 45.06万
  • 项目类别:
Active Viral Hepatitis Diagnostics to Support Prevention/Treatment of HCC
主动病毒性肝炎诊断支持 HCC 的预防/治疗
  • 批准号:
    8929186
  • 财政年份:
    2014
  • 资助金额:
    $ 45.06万
  • 项目类别:
Northwestern and Jos University Research Training Program in HIV and Malignancies
西北大学和乔斯大学艾滋病毒和恶性肿瘤研究培训项目
  • 批准号:
    8710899
  • 财政年份:
    2014
  • 资助金额:
    $ 45.06万
  • 项目类别:
Northwestern and Jos University Research Training Program in HIV and Malignancies
西北大学和乔斯大学艾滋病毒和恶性肿瘤研究培训项目
  • 批准号:
    9117765
  • 财政年份:
    2014
  • 资助金额:
    $ 45.06万
  • 项目类别:
Developing Innovative Interdisciplinary Biomedical Engineering Programs in Africa
在非洲开发创新的跨学科生物医学工程项目
  • 批准号:
    8598381
  • 财政年份:
    2013
  • 资助金额:
    $ 45.06万
  • 项目类别:
Developing Innovative Interdisciplinary Biomedical Engineering Programs in Africa
在非洲开发创新的跨学科生物医学工程项目
  • 批准号:
    8742030
  • 财政年份:
    2013
  • 资助金额:
    $ 45.06万
  • 项目类别:
Northwestern University Clinical Trial Unit
西北大学临床试验中心
  • 批准号:
    8138247
  • 财政年份:
    2010
  • 资助金额:
    $ 45.06万
  • 项目类别:
Northwestern University AITRP
西北大学AITRP
  • 批准号:
    8107503
  • 财政年份:
    2008
  • 资助金额:
    $ 45.06万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.06万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了